BMS's kingly Opdivo NSCLC data

Bristol-Myers Squibb Co. (NYSE:BMY) said it ended the Phase III CheckMate -017 trial of Opdivo nivolumab to treat advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) after

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE